Abstract Background Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence. characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds. inotuzumab ozogamicin (IO) is a promising drug. https://jalyttlers.shop/product-category/bedlinen/